Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $50M (up 202.7% year over year) with net income of −$30M.
Q3 2025 key financials · XBRL
- Revenue
- $50M
- +202.7% YoY · +25.3% QoQ
- Net income
- −$30M
- +65.0% YoY · +60.5% QoQ
- Operating margin
- -30.9%
- Gross margin
- 87.5%
- EPS (diluted)
- −$0.40
- +69.5% YoY · +61.9% QoQ
Source: XBRL data from the Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 10-Q on SEC EDGAR. USD.
Phathom Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 product revenue $49.5M vs $16.4M, up $33.2M YoY
- Gross margin 87.5% vs 85.6% YoY; operating loss $15.3M vs $70.8M
- VOQUEZNA tablets, Triple Pak, and Dual Pak generated revenue; Triple Pak approximately 1% of total revenue
- Cash and equivalents $135.2M at September 30, 2025; sufficient for at least twelve months
- Near-term clarithromycin supply disruption not currently anticipated; continued monitoring planned
Risk Factors
- No material changes to 2024 Form 10-K risk factors, as updated through March 31, 2025
- No newly added risk factor or disclosed trigger during the quarter
- Regulatory compliance: Rule 10b5-1 sell-to-cover arrangements terminated following net settlement approval
- Equity-award administration: arrangements for Cook, Basta, and Breedlove terminated September 24–October 9, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Phathom Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.